Virtu Financial LLC Exelixis, Inc. Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$14.96 - $17.39 $192,924 - $224,261	-12,896 Reduced 54.07%	10,953 $176,000
Q3 2022 Nov 07, 2022	BUY	$15.68 - $22.27 $18,690 - $26,545	1,192 Added 5.26%	23,849 $374,000
Q2 2022 Aug 09, 2022	BUY	$17.44 - $23.16 $395,138 - $524,736	22,657 New	22,657 $472,000
Q1 2021 May 19, 2021	SELL	$20.53 - $25.22 $355,169 - $436,306	-17,300 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$18.39 - $24.8 $318,147 - $429,040	17,300 New	17,300 $347,000
Q2 2020 Aug 07, 2020	SELL	$16.46 - $27.42 $260,068 - $433,236	-15,800 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$15.15 - $18.89 $599,227 - $747,156	-39,553 Reduced 71.46%	15,800 $278,000
Q3 2019 Nov 20, 2019	BUY	$17.68 - $22.65 $507,080 - $649,624	28,681 Added 107.53%	55,353 $979,000
Q2 2019 Aug 13, 2019	BUY	$18.93 - $24.75 $280,296 - $366,473	14,807 Added 124.8%	26,672 $570,000
Q1 2019 Apr 12, 2019	SELL	$19.6 - $24.76 $998,659 - $1.26 Million	-50,952 Reduced 81.11%	11,865 $282,000
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $1.39 Million - $2 Million	62,817 New	62,817 $1.39 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.